(Q39418071)

11 September 2017

Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin (English)

1 reference

11 September 2017

0 references

H Landen

1

1 reference

11 September 2017

M Möller

2

1 reference

11 September 2017

G S Tillotson

3

1 reference

11 September 2017

R Kubin

4

1 reference

11 September 2017

G Höffken

5

1 reference

11 September 2017

language of work or name

1 reference

1 March 2001

1 reference

Journal of International Medical Research

11 September 2017

1 reference

11 September 2017

29

1 reference

11 September 2017

2

1 reference

11 September 2017

51-60

1 reference

Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema

11 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F147323000102900202

Crossref

reference URL

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000102900202

Crossref

reference URL

The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000102900202

Crossref

reference URL

10.1177/147323000102900202

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference